Figure 1
Figure 1. GEP70 risk, IgH, and MYC translocations and nonsilent mutations in selected genes. (A) The risk status according to the recently published 3-group GEP70 classifier11 is shown for the 33 patients. Intermediate-risk cases would be classified as low risk according to the classical GEP70.10 UAMS GEP groups are shown within the boxes, consisting of CD-1, CD-2, HY, LB, MS, MF, and PR. The upper and lower rows present the status at presentation and relapse, respectively. (B) IgH and MYC translocations were called from whole-exome sequencing data using MANTA16 and are shown with the corresponding translocation partner chromosome. C: Non-silent SNVs and indels in a set of genes previously implicated in the pathogenesis of MM.17,18 CoLRs indicate whether an abnormality was detected at presentation, relapse, or both.

GEP70 risk, IgH, and MYC translocations and nonsilent mutations in selected genes. (A) The risk status according to the recently published 3-group GEP70 classifier11  is shown for the 33 patients. Intermediate-risk cases would be classified as low risk according to the classical GEP70.10  UAMS GEP groups are shown within the boxes, consisting of CD-1, CD-2, HY, LB, MS, MF, and PR. The upper and lower rows present the status at presentation and relapse, respectively. (B) IgH and MYC translocations were called from whole-exome sequencing data using MANTA16  and are shown with the corresponding translocation partner chromosome. C: Non-silent SNVs and indels in a set of genes previously implicated in the pathogenesis of MM.17,18  CoLRs indicate whether an abnormality was detected at presentation, relapse, or both.

Close Modal

or Create an Account

Close Modal
Close Modal